ArticleBlood2020
Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic.
Article in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Trial
- Incidence and Risk Factors for New and Recurrent Infarcts in Adults With Sickle Cell Disease.Journal of the American Heart Association · 2024Observational
- Provider prescription of hydroxyurea in youth and adults with sickle cell disease: A review of prescription barriers and facilitators.British journal of haematology · 2023Review
- Covid-19 impacts: Ethnic and regional inequalities in sickle cell disease patient care in Brazil.Heliyon · 2023Article
- Review
- Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches.Blood · 2022Article
- Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications.International journal of molecular sciences · 2021Review
- Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios.Cancers · 2021Review
- COVID-19 pandemic and transfusion medicine: the worldwide challenge and its implications.Annals of hematology · 2021Review
- A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic.Orphanet journal of rare diseases · 2021Review
- Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation.Nature reviews. Cardiology · 2021Review
- The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2021Review
- COVID-19 and sickle cell disease.Haematologica · 2020Article
- [Influence of COVID-19 on the occurrence and treatment of hemolytic diseases].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Care of patients with hemoglobin disorders during the COVID-19 pandemic: An overview of recommendations.American journal of hematology · 2020Article
- Article
- Management of Hemoglobin Disorders During the COVID-19 Pandemic.Frontiers in medicine · 2020Review
- Psoriasis Management During the COVID-19 Pandemic: Recommendations by SIG Psoriasis (IADVL Academy).Indian dermatology online journalArticle
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.